Tetraneuron
Web: http://tetraneuron.com/es/
Founding Year: 2013
Industries: biotechnology
Business Model: manufacturing
Income Stream: selling own inventory
Business Focus: B2B
Short Description (in English): Developing gene therapies for neurodegenerative diseases.
Overview (in English): Tetraneuron is a company focused on developing innovative gene therapies for neurodegenerative diseases. Their approach involves gene therapy targeting E2F4 to restore biological processes affected by E2F4 phosphorylation. Their team has over 30 years of experience in neuroscience.
See profile on the Startup Radar madri+d platform on Dealroom:
News and Interviews
- Dic 09, 2025 Spanish biotech Tetraneuron secures funding for Alzheimer's gene therapy clinical trials
- Jul 14, 2023 El Vehículo De Inversión Biozell Ventures Apuesta Por La Terapia Génica De Tetraneuron
- Ene 09, 2023 La Biotech Tetraneuron Logra 5M€ Para Seguir Avanzando En La Lucha Contra El Alzheimer
- Dic 27, 2022 Tetraneuron Alcanza Los €5 Millones En Una Ronda Para Su Terapia Génica Contra El Alzhéimer
- Ene 10, 2022 Tetraneuron will receive 1M€ from the IVF and FEDER to advance its therapy against Alzheimer's Disease - Tetraneuron
- Jun 28, 2021 Spanish biotech Tetraneuron raises more than 2.5 million euros to advance its Alzheimer's therapy - Tetraneuron